@article {7521,
	title = {Competing risk survival analysis in patients with symptomatic waldenstr{\"o}m macroglobulinemia: The impact of disease unrelated mortality and of rituximab-based primary therapy},
	journal = {Haematologica},
	volume = {100},
	year = {2015},
	note = {Cited By :4Export Date: 21 February 2017},
	month = {2015},
	pages = {e448 - e449},
	keywords = {age, Cyclophosphamide, Fludarabine, Lymphoma, Prognosis, rituximab},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946203324\&doi=10.3324\%2fhaematol.2015.124149\&partnerID=40\&md5=c7c2fc68f3500c1f7b6b452711f16861},
	author = {Kastritis, E. and Kyrtsonis, M.-C. and Morel, P. and Gavriatopoulou, M. and Hatjiharissi, E. and Symeonidis, A.S. and Vassou, A. and Repousis, P. and Delimpasi, S. and Sioni, A. and Michalis, E. and Michael, M. and Vervessou, E. and Voulgarelis, M. and Tsatalas, C. and Terpos, E. and Dimopoulos, M.A.}
}
